245 related articles for article (PubMed ID: 38474223)
1. Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency.
Liongue C; Ratnayake T; Basheer F; Ward AC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474223
[TBL] [Abstract][Full Text] [Related]
2. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
3. The molecular regulation of Janus kinase (JAK) activation.
Babon JJ; Lucet IS; Murphy JM; Nicola NA; Varghese LN
Biochem J; 2014 Aug; 462(1):1-13. PubMed ID: 25057888
[TBL] [Abstract][Full Text] [Related]
4. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
Vainchenker W; Dusa A; Constantinescu SN
Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
[TBL] [Abstract][Full Text] [Related]
5. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
6. JAK3: a two-faced player in hematological disorders.
Cornejo MG; Boggon TJ; Mercher T
Int J Biochem Cell Biol; 2009 Dec; 41(12):2376-9. PubMed ID: 19747563
[TBL] [Abstract][Full Text] [Related]
7. JAK and MPL mutations in myeloid malignancies.
Tefferi A
Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515
[TBL] [Abstract][Full Text] [Related]
8. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of Janus kinase trans-activation.
Caveney NA; Saxton RA; Waghray D; Glassman CR; Tsutsumi N; Hubbard SR; Garcia KC
Cell Rep; 2023 Mar; 42(3):112201. PubMed ID: 36867534
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
11. Janus Kinase 3 phosphorylation and the JAK/STAT pathway are positively modulated by follicle-stimulating hormone (FSH) in bovine granulosa cells.
Zareifard A; Beaudry F; Ndiaye K
BMC Mol Cell Biol; 2023 Jun; 24(1):21. PubMed ID: 37337185
[TBL] [Abstract][Full Text] [Related]
12. JAK: Not Just Another Kinase.
Agashe RP; Lippman SM; Kurzrock R
Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
[TBL] [Abstract][Full Text] [Related]
13. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.
Grant AH; Rodriguez AC; Rodriguez Moncivais OJ; Sun S; Li L; Mohl JE; Leung MY; Kirken RA; Rodriguez G
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047778
[TBL] [Abstract][Full Text] [Related]
14. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.
Saharinen P; Silvennoinen O
J Biol Chem; 2002 Dec; 277(49):47954-63. PubMed ID: 12351625
[TBL] [Abstract][Full Text] [Related]
15. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase 3: the controller and the controlled.
Wu W; Sun XH
Acta Biochim Biophys Sin (Shanghai); 2012 Mar; 44(3):187-96. PubMed ID: 22130498
[TBL] [Abstract][Full Text] [Related]
17. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
[TBL] [Abstract][Full Text] [Related]
18. JAK kinases overexpression promotes in vitro cell transformation.
Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
[TBL] [Abstract][Full Text] [Related]
19. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
20. Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor gamma(c) chain for Janus kinase activation leading to T cell proliferation.
Nelson BH; McIntosh BC; Rosencrans LL; Greenberg PD
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1878-83. PubMed ID: 9050873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
